SLC5A2 and cancer: In another study, in-vitro treatment with SGLT2 inhibitors demonstrated disruption of adhesion capacity of certain cancer cells and suppression of oxidative phosphorylation via inhibition of mitochondrial electron transport chain in HCC, breast, prostate, and lung cancer cells [228,235,236].